ConductScience.org, home
Diseases
API referenceFor AI assistants

Disease · MONDO_0005961

sinusitis

6 sourcesdiseases-2026-09-18-0.1.0

Download JSON
Cite this record

ConductScience Library. sinusitis. Diseases, record MONDO_0005961. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005961

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name
sinusitis
Open Targets
Open Targets ID
MONDO_0005961
Open Targets
Disease Ontology
DOID:0050127
Disease Ontology
MeSH
D012852
MeSH
NCI Thesaurus
C35024
NCI Thesaurus
Highest stage of its drugs
Approval, for 27 of its 47 drugs, from DailyMed, EMA Human Drugs and PMDA
Open Targets

Drugs47

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

DrugChEMBL IDTypeOpen Targets' stageStage reported byReportsOf them trialsTrials shown hereSource
AMOXICILLINCHEMBL1082Small moleculeApprovalDailyMed6033Drugs and targets
DUPILUMABCHEMBL2108675AntibodyApprovalEMA Human Drugs433Drugs and targets
CLAVULANATE POTASSIUMCHEMBL1003Small moleculeApprovalDailyMed5511Drugs and targets
PSEUDOEPHEDRINE HYDROCHLORIDECHEMBL1200724Small moleculeApprovalDailyMed411Drugs and targets
AZITHROMYCINCHEMBL529Small moleculeApprovalDailyMed311Drugs and targets
LEVOFLOXACINCHEMBL5315124Small moleculeApprovalDailyMed211Drugs and targets
EPINEPHRINECHEMBL679Small moleculeApprovalDailyMed1100Drugs and targets
PHENYLEPHRINE HYDROCHLORIDECHEMBL1200339Small moleculeApprovalDailyMed900Drugs and targets
ACETAMINOPHENCHEMBL112Small moleculeApprovalDailyMed400Drugs and targets
BROMPHENIRAMINE MALEATECHEMBL1200961Small moleculeApprovalDailyMed400Drugs and targets

1 to 10 of 47

See all 47 drugs

Targets42

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

TargetProteinIts drugs that act on itMechanismsHighest stage of those drugsGene in GenesSource
NR3C1Glucocorticoid receptor6Glucocorticoid receptor agonistPhase 3https://conductscience.org/library/genes/2908Drugs and targets
ADRA1AAdrenergic receptor4Adrenergic receptor agonist; Adrenergic receptor alpha agonist; Adrenergic receptor alpha-1 agonistApprovalhttps://conductscience.org/library/genes/148Drugs and targets
ADRA1BAdrenergic receptor4Adrenergic receptor agonist; Adrenergic receptor alpha agonist; Adrenergic receptor alpha-1 agonistApprovalhttps://conductscience.org/library/genes/147Drugs and targets
ADRA1DAdrenergic receptor4Adrenergic receptor agonist; Adrenergic receptor alpha agonist; Adrenergic receptor alpha-1 agonistApprovalhttps://conductscience.org/library/genes/146Drugs and targets
ADRA2AAdrenergic receptor4Adrenergic receptor agonist; Adrenergic receptor alpha agonist; Adrenergic receptor alpha-2 agonistApprovalhttps://conductscience.org/library/genes/150Drugs and targets
ADRA2BAdrenergic receptor4Adrenergic receptor agonist; Adrenergic receptor alpha agonist; Adrenergic receptor alpha-2 agonistApprovalhttps://conductscience.org/library/genes/151Drugs and targets
ADRA2CAdrenergic receptor4Adrenergic receptor agonist; Adrenergic receptor alpha agonist; Adrenergic receptor alpha-2 agonistApprovalhttps://conductscience.org/library/genes/152Drugs and targets
GUCY1A1Soluble guanylate cyclase2Soluble guanylate cyclase activatorPhase 2https://conductscience.org/library/genes/2982Drugs and targets
GUCY1A2Soluble guanylate cyclase2Soluble guanylate cyclase activatorPhase 2https://conductscience.org/library/genes/2977Drugs and targets
GUCY1B1Soluble guanylate cyclase2Soluble guanylate cyclase activatorPhase 2https://conductscience.org/library/genes/2983Drugs and targets

1 to 10 of 42

See all 42 targets

Trials27

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.

TrialTitlePhaseParticipantsResults first postedConditionsDrugsLinked bySource
NCT04123405Efficacy and Safety of Acetylcysteine for the Treatment of Acute Uncomplicated RhinosinusitisPhase 39442021-11-19RhinosinusitisACETYLCYSTEINEOpen Targets' reading of its recordClinicalTrials.gov
NCT03781804Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Rhinosinusitis With or Without the Presence of Nasal PolypsPhase 33322023-09-18Chronic RhinosinusitisFLUTICASONE PROPIONATEOpen Targets' reading of its recordClinicalTrials.gov
NCT01222832Effectiveness of Antibiotic Delivery Via Bio-absorbable SpongePhase 22262017-05-31Paranasal Sinus DiseaseBACITRACINIts record names the diseaseClinicalTrials.gov
NCT03960580Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Rhinosinusitis Without the Presence of Nasal PolypsPhase 32232023-12-21Chronic RhinosinusitisFLUTICASONE PROPIONATEOpen Targets' reading of its recordClinicalTrials.gov
NCT04041609LYR-210 Depot (LYR-210) for Adult Subjects With Chronic Sinusitis (LANTERN Study)Phase 2712023-06-06Chronic Sinusitis, Chronic Rhinosinusitis (Diagnosis)MOMETASONE FUROATEOpen Targets' reading of its recordClinicalTrials.gov
NCT04684524Dupilumab in Allergic Fungal Rhinosinusitis (AFRS)Phase 3622025-12-22Allergic Fungal RhinosinusitisDUPILUMABOpen Targets' reading, confirmed by NLM's indexing of its papersClinicalTrials.gov
NCT01920893An Evaluation of Dupilumab in Patients With Nasal Polyposis And Chronic Symptoms Of SinusitisPhase 2602017-06-02Nasal PolypsDUPILUMAB, MOMETASONE FUROATEIts record names the diseaseClinicalTrials.gov
NCT00747747Sinuclean's Treatment Of Sinusitis' SymptomsPhase 4492012-03-14SinusitisAMOXICILLINIts record names the diseaseClinicalTrials.gov
NCT01988779Oral Versus Topical Antibiotics for Chronic Rhinosinusitis ExacerbationsPhase 3332019-12-11Chronic RhinosinusitisLEVOFLOXACINOpen Targets' reading of its recordClinicalTrials.gov
NCT01066104Subcutaneous Omalizumab for Treatment of Chronic Rhinosinusitis With Nasal PolyposisPhase 2272017-05-19Chronic Rhinosinusitis, Nasal PolypsOMALIZUMABOpen Targets' reading of its recordClinicalTrials.gov

1 to 10 of 27

See all 27 trials

Comparisons in its trials18

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

ComparisonGroup 1, with the outcomeGroup 2, with the outcomeParticipantsTrialSource
Bacitracin vs Saline: deaths from any cause0 of 1130 of 113226NCT01222832Trial comparisons
Bacitracin vs Saline: Rate of Infection113 of 113113 of 113226NCT01222832Trial comparisons
Bacitracin vs Saline: serious adverse events0 of 1130 of 113226NCT01222832Trial comparisons
Dupilumab vs Placebo: deaths from any cause0 of 330 of 2861NCT04684524Trial comparisons
Dupilumab vs Placebo: serious adverse events0 of 333 of 2861NCT04684524Trial comparisons
Dupilumab 300 mg QW vs Placebo: deaths from any cause0 of 300 of 3060NCT01920893Trial comparisons
Dupilumab 300 mg QW vs Placebo: serious adverse events2 of 304 of 3060NCT01920893Trial comparisons
Dupilumab vs Placebo: Number of Participants With Treatment-emergent Anti-drug Antibodies (ADA) to Dupilumab1 of 220 of 1941NCT04684524Trial comparisons
Xolair (Omalizumab) vs Xolair Placebo: deaths from any cause0 of 130 of 1427NCT01066104Trial comparisons
Xolair (Omalizumab) vs Xolair Placebo: serious adverse events0 of 130 of 1427NCT01066104Trial comparisons

1 to 10 of 18

See all 18 comparisons in its trials

Papers from its trials28

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMIDListed asTrials listing itSource
28390807RESULT1PubMed
27394715RESULT1PubMed
26836729RESULT1PubMed
24594542RESULT1PubMed
23785241RESULT1PubMed
23378777RESULT1PubMed
21994147RESULT1PubMed
17882910RESULT1PubMed
17405780RESULT1PubMed
16337461RESULT1PubMed

1 to 10 of 28

See all 28 papers from its trials

Data dates

The date of each source this release read.

Open Targets
2026-09-18
Open Targets
Drug links and their checks, from Drugs and targets
2026-09-18
Drugs and targets
ClinicalTrials.gov, from Trials
2026-11-12
Trials
Comparisons, from Trial comparisons
2026-03-23
Trial comparisons
PubMed, for the checks
2026-11-06
PubMed
MeSH, for the checks
2026-11-10
MeSH

Sources 6

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • NLM's MeSHNLM's terms
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • NLM's MeSHNLM's
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005961

GET https://conductscience.org/api/diseases/v1/MONDO_0005961/drugs?page=2

API referenceFor AI assistants